Connect with us


Successful Weight-Loss Drug Trial Shows Promise for Sleep Apnea Patients, Finds Eli Lilly – ET HealthWorld



Eli Lilly's weight-loss drug succeeds in trials with sleep apnea patients, ET HealthWorld

In a recent development, Eli Lilly has announced promising results from two late-stage trials of their weight-loss drug in patients with obstructive sleep apnea. The drug showed a significant reduction in the frequency of irregular breathing by up to 63%. This breakthrough comes as weight-loss drugs like Lilly’s Zepbound and Novo Nordisk’s Wegovy, known as GLP-1 agonists, have gained traction in the market for treating obesity and diabetes.

The trials revealed that GLP-1 drugs, by reducing food cravings and slowing stomach emptying, could potentially offer medical benefits beyond their initial purposes. Patients who received tirzepatide, the active ingredient in Lilly’s drugs, showed a remarkable 55% improvement in symptoms compared to those on a placebo. Moreover, combining the drug with continuous positive airway pressure (CPAP) therapy led to a 62.8% decrease in irregular breathing events on average.

With approximately 1 billion individuals worldwide affected by obstructive sleep apnea, the significance of these findings cannot be understated. The studies utilized the Apnea-Hypopnea Index (AHI) to measure the severity of airway obstructions during sleep. Lilly intends to submit the data to regulatory authorities like the FDA for further evaluation and potential approval.

This breakthrough not only opens new possibilities for the use of GLP-1 drugs in treating sleep apnea but also underscores the potential of these medications in addressing a broader range of medical conditions. As the pharmaceutical industry continues to innovate, patients may soon have access to more effective and multifaceted treatments for various health issues.

Click to comment

You must be logged in to post a comment Login

Leave a Reply